Published in Lab Business Week, September 18th, 2005
Sevin Rosen Funds led the $11.1 million round and was joined by Ventures West, WRF Capital and other private investors.
"This financing is proof that the investment community is recognizing the value of our technologies and their enormous potential within the field of antibody therapeutics," said Randall Schatzman, CEO and an Alder founder. "This funding will allow us to develop our lead antibody therapeutic, broaden our product pipeline, and build on our proprietary antibody discovery and manufacturing technologies."
Alder's proprietary technologies...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Lab Business Week